Collaborative Research Programme in Biomedical Innovation Law (CeBIL)
The Novo Nordisk Foundation has provided a grant to the Collaborative Research Programme in Biomedical Innovation Law (CeBIL) to “address and scrutinize the most significant legal challenges to biomedical innovation and public health from a holistic cross-disciplinary perspective.”
“The overall aim and ambition of CeBIL is to contribute to the translation of groundbreaking biomedical research into safe, effective, affordable and accessible therapies by analyzing the most significant legal challenges to pharmaceutical innovation and public health from a holistic cross-disciplinary perspective.”
Source & more information: jura.ku.dk/cebil
“The CeBIL research projects will be carried out with several core partners. These are expected to include internationally renowned experts at Harvard Medical School/Brigham and Women’s Hospital, University of Cambridge, University of Michigan, and UCPH’s Department of Food and Resource Economics (IFRO). Moreover, CeBIL will collaborate with a broad network of stakeholder organizations and international experts within law, economics, life science, medicine, sociology and pharmacy. This involves special advisors from the Max Planck Institute for Innovation & Competition, Massachusetts Institute of Technology (MIT), Boston University, the Universities of Oxford, Pennsylvania, Michigan and Hong Kong, as well as UCPH’s Department of Public Health and the Copenhagen Centre for Regulatory Sciences (CORS).”
Source & announcement: news.ku.dk/all_news/2017/11/new-interdisciplinary-research-programme-in-biomedical-innovation-law
